Novartis biosimilar matches Amgen''s bone disorder drug Prolia, meeting trial''s goal
Novartis (NVS) said its potential biosimilar of Amgen''s (AMGN) bone disorder drug Prolia (denosumab) was as good as the reference product.The phase 1|3 trial,…
Novartis biosimilar matches Amgen''s bone disorder drug Prolia, meeting trial''s goal
Novartis (NVS) said its potential biosimilar of Amgen''s (AMGN) bone disorder drug Prolia (denosumab) was as good as the reference product.The phase 1|3 trial,…